Bioinformatics Analysis Of Omics Data For Biomarker Identification In Clinical Research Volume Ii

This Research Topic is part of a series with, "Bioinformatics Analysis of Omics Data for Biomarker Identification in Clinical Research - Volume I" (https://www.frontiersin.org/research-topics/13816/bioinformatics-analysis-of-omics-data-for-biomarker-identification-in-clinical-research) The advances and the decreasing cost of omics data enable profiling of disease molecular features at different levels, including bulk tissues, animal models, and single cells. Large volumes of omics data enhance the ability to search for information for preclinical study and provide the opportunity to leverage them to understand disease mechanisms, identify molecular targets for therapy, and detect biomarkers of treatment response. Identification of stable, predictive, and interpretable biomarkers is a significant step towards personalized medicine and therapy. Omics data from genomics, transcriptomics, proteomics, epigenomics, metagenomics, and metabolomics help to determine biomarkers for prognostic and diagnostic applications. Preprocessing of omics data is of vital importance as it aims to eliminate systematic experimental bias and technical variation while preserving biological variation. Dozens of normalization methods for correcting experimental variation and bias in omics data have been developed during the last two decades, while only a few consider the skewness between different sample states, such as the extensive over-repression of genes in cancers. The choice of normalization methods determines the fate of identified biomarkers or molecular signatures. From these considerations, the development of appropriate normalization methods or preprocessing strategies may promote biomarker identification and facilitate clinical decision-making.

Presenting an area of research that intersects with and integrates diverse disciplines, including molecular biology, applied informatics, and statistics, among others, Bioinformatics for Omics Data: Methods and Protocols collects contributions from expert researchers in order to provide practical guidelines to this complex study. Divided into three convenient sections, this detailed volume covers central analysis strategies, standardization and data-management guidelines, and fundamental statistics for analyzing Omics profiles, followed by a section on bioinformatics approaches for specific Omics tracks, spanning genome, transcriptome, proteome, and metabolome levels, as well as an assortment of examples of integrated Omics bioinformatics applications, complemented by case studies on biomarker and target identification in the context of human disease. Written in the highly successful Methods in Molecular BiologyTM series format, chapters contain introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and notes on troubleshooting and avoiding known pitfalls. Authoritative and accessible, Bioinformatics for Omics Data: Methods and Protocols serves as an ideal guide to scientists of all backgrounds and aims to convey the appropriate sense of fascination associated with this research field.

This book is designed to introduce biologists, clinicians and computational researchers to fundamental data analysis principles, techniques and tools for supporting the discovery of biomarkers and the implementation of diagnostic/prognostic systems. The focus of the book is on how fundamental statistical and data mining approaches can support biomarker discovery and evaluation, emphasising applications based on different types of "omic" data. The book also discusses design factors, requirements and techniques for disease screening, diagnostic and prognostic applications. Readers are provided with the knowledge needed to assess the requirements, computational approaches and outputs in disease biomarker research. Commentaries from guest experts are also included, containing detailed discussions of methodologies and applications based on specific types of "omic" data, as well as their integration. Covers the main range of data sources currently used for biomarker discovery Covers the main range of data sources currently used for biomarker discovery Puts emphasis on concepts, design principles and methodologies that can be extended or tailored to more specific applications Offers principles and methods for assessing the bioinformatic/biostatistic limitations, strengths and challenges in biomarker discovery studies Discusses systems biology approaches and applications Includes expert chapter commentaries to further discuss relevance of techniques, summarize biological/clinical implications and provide alternative interpretations

This book serves as an introduction to genomics, proteomics, and transcriptomics, putting these fields in relation to human disease and ailments. The various chapters consider the role of translation and personalized medicine, as well as pathogen detection, evolution, and infection, in relation to genomics, proteomics, and transcriptomics. The topic of companion diagnostics is also covered. The book is broken into five sections. Part I examines the connection between omics and human disease. Part II looks at the applications for the fields of translational and personalized medicine. Part III focuses on molecular and genetic markers. Part IV describes the use of omics while studying pathogens, and Part V examines the applications for companion diagnostics. The book: • Introduces genomics, proteomics, and transcriptomics in relation to human disease and ailments • Considers the role of translation and personalized medicine in relation to genomics, proteomics, and transcriptomics • Covers molecular and genetic markers • Considers the role of genomics, proteomics, and transcriptomics in relation to pathogen detection, evolution, and infection • Covers companion diagnostics in relation to genomics, proteomics, and transcriptomics clinical applications and research

Technologies collectively called omics enable simultaneous measurement of an enormous number of biomolecules; for example, genomics investigates thousands of DNA sequences, and proteomics examines large numbers of proteins. Scientists are using these technologies to develop innovative tests to detect disease and to predict a patient's likelihood of responding to specific drugs. Following a recent case involving premature use of omics-based tests in cancer clinical trials at Duke University, the NCI requested that the IOM establish a committee to recommend ways to strengthen omics-based test development and evaluation. This report identifies best practices to enhance development, evaluation, and translation of omics-based tests while simultaneously reinforcing steps to ensure that these tests are appropriately assessed for scientific validity before they are used to guide patient treatment in clinical trials.

Covering the latest developments in clinical omics, this volume details the algorithms currently used in publicly available software tools. It looks at statistics, algorithms, automated data retrieval, and experimental consideration in the various omics areas.